Publications
Litigation Packet
Litigation Packet
Risperdal
$249.00
Delivery method: Download
- Risperdal, an atypical (second generation) antipsychotic originally approved for the treatment of schizophrenia and Bipolar I disorder in adults but marketed off-label to children and adolescents, can increased prolactin levels and cause irreversible gynecomastia
- Includes case screening criteria, a sample complaint, and an overview of litigation
- Includes pleadings and orders from three mass tort actions in Pennsylvania, New Jersey, and California
- AAJ Education speaker papers, resources from the U.S. Food and Drug Administration, and a survey of medical journal articles
